Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

⟵ Back to Search Results

Beigene Study ID

BGB-A317-314

ClinicalTrials.gov ID

NCT04486391

China Drug Trials ID

CTR20201517

Sex: All

Age: 18 Years / N/A

No Study Documents

Locations

Sex: All

Age: 18 Years / N/A

No Study Documents